CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04637763
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:42.981783+00:00
Published At: 2025-03-24T00:00:00+00:00
Record Updated At: 2025-03-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, Non-Hodgkin", "Relapsed Non Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Lymphoma", "B Cell Lymphoma", "B Cell Non-Hodgkin\u0027s Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-24"
protocolSection.identificationModule.nctId: "NCT04637763"
protocolSection.identificationModule.officialTitle: "A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.